The FDA approved a biosimilar to treat RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
The FDA approved a biosimilar to treat RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
The FDA approved a biosimilar to treat RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
The FDA has approved Afluria Quadrivalent for the use in individuals 18 years and older for active immunization against influenza cause by influenza A and B viruses.
The FDA has approved Afluria Quadrivalent for the use in individuals 18 years and older for active immunization against influenza cause by influenza A and B viruses.
The FDA has approved Afluria Quadrivalent for the use in individuals 18 years and older for active immunization against influenza cause by influenza A and B viruses.